Compare · EVMN vs NVO
EVMN vs NVO
Side-by-side comparison of Evommune Inc. (EVMN) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EVMN and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.95B, about 527.8x EVMN ($409.2M).
- Over the past year, EVMN is down 42.5% and NVO is down 29.3% - NVO leads by 13.2 points.
- NVO has been more active in the news (4 items in the past 4 weeks vs 3 for EVMN).
- NVO has more recent analyst coverage (25 ratings vs 12 for EVMN).
- Company
- Evommune Inc.
- Novo Nordisk A/S
- Price
- $11.37+0.35%
- $48.78+1.22%
- Market cap
- $409.2M
- $215.95B
- 1M return
- -51.66%
- +2.89%
- 1Y return
- -42.49%
- -29.29%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2025
- News (4w)
- 3
- 4
- Recent ratings
- 12
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest EVMN
- SEC Form SCHEDULE 13G filed by Evommune Inc.
- Chief Financial Officer Carver Kyle bought $13,260 worth of shares (1,000 units at $13.26), increasing direct ownership by 2% to 60,335 units (SEC Form 4)
- Director Kirsch Arthur S bought $133,000 worth of shares (10,000 units at $13.30) (SEC Form 4)
- Evommune downgraded by H.C. Wainwright
- Evommune downgraded by William Blair
- SEC Form 424B3 filed by Evommune Inc.
- Evommune Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Evommune Announces Top-line Results from EVO756 Phase 2b Trial in Moderate-to-Severe Chronic Spontaneous Urticaria
- Chief of Dev. Operations Drew Janice Suzann exercised 20,000 shares at a strike of $3.15 and sold $452,600 worth of shares (20,000 units at $22.63) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Scientific Officer Patel Jeegar Pravinkumar exercised 1,488 shares at a strike of $3.84 and sold $33,480 worth of shares (1,488 units at $22.50) as part of a pre-agreed trading plan (SEC Form 4)
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- One Formula, One Platform: Inside the Preclinical Milestone Behind Conexeu's Move Into Medical Aesthetics
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S